HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy

Pathology Research and Practice

Volumn 201, Issue 2, 2005, Pages 141-144

  Raspollini, Maria Rosaria ^a   Mecacci, Federico ^a   Paglierani, Milena ^a   Marchionni, Mauro ^a   Taddei, Gian Luigi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carcinosarcoma; Estrogen; HER 2 neu; Tamoxifen; Uterus

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; BREAST CANCER; CANCER RESEARCH; CARCINOGENESIS; CASE REPORT; CHROMOSOME 1; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; ECHOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; LYMPHADENECTOMY; MASTECTOMY; POSTOPERATIVE PERIOD; PROGNOSIS; SALPINGOOOPHORECTOMY; TUMOR BIOPSY; UTERUS SARCOMA;

EID: 15944370012     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prp.2004.11.009     Document Type: Article

References (21)

1. K.W. Barwick V.A. LiVolsi Malignant mixed mullerian tumors of the uterus: A clinicopathologic assessment of 34 cases Am. J. Surg. Pathol. 3 1979 125-135
2. M.R. Clarke Uterine malignant mixed mullerian tumor in a patient on long-term tamoxifen therapy for breast cancer Gynecol. Oncol. 51 1993 411-415
3. P.B. Clement E. Oliva R.H. Young Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: A report of six cases and a review of tamoxifen-associated endometrial lesions Int. J. Gynecol. Pathol. 15 1996 222-229
4. T.V. Dinh R.E. Slavin B.S. Bhagavan E.V. Hannigan E.M. Tiamson R.B. Yandell Mixed mullerian tumors of the uterus: A clinicopathologic study Obstet. Gynecol. 74 1989 388-392
5. Early Breast Cancer Collaborative Group Tamoxifen for early breast cancer: An overview of the randomised trial Lancet 351 1998 1467-1471
6. R. Fossati C. Confalonieri V. Torri E. Ghislandi A. Penna V. Pistotti A. Tinazzi A. Liberati Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31510 women J. Clin. Oncol. 16 1998 3439-3460
7. B.J.A. Furr V.C. Jordan The pharmacology and clinical uses of tamoxifen Pharmacol. Ther. 25 1984 127-205
8. C.T. Guy M.A. Webster M. Schaller T.J. Parsons R.D. Cardiff W.J. Muller Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease Proc. Natl. Acad. Sci. USA 89 1992 10,578-10,582
9. Y. Iwasa H. Haga I. Konishi Y. Kobashi K. Higuchi E. Katsuyama S. Minamiguchi H. Yamabe Prognostic factors in uterine carcinosarcoma. A clinicopathologic study of 25 patients Cancer 82 1998 512-519
10. P. Mhawech A.T. Vlastos M.F. Pelte Uterine polypoid mass in a postmenopausal patient following tamoxifen treatment for breast cancer Arch. Pathol. Lab. Med. 126 2002 1125-1126
11. S.N. Nielsen K.C. Podratz B.W. Scheithauer P.C. O'Brien Clinicopathologic analysis of uterine malignant mixed mullerian tumors Gynecol. Oncol. 34 1989 372-378
12. M.A. Olayioye R.M. Neve H.A. Lane N.E. Hynes The ErbB signaling network: receptor heterodimerization in the development and cancer EMBO J. 19 2000 3159-3167
13. E.S. Podczaski C.A. Woomert C.W. Stevens Jr. A. Manetta J.E. Larson R.J. Zaino R. Mortel Management of malignant, mixed mesodermal tumors of the uterus Gynecol. Oncol. 32 1989 240-244
14. S.J. Robboy M.C. Anderson P. Russel Pathology of the Female Reproductive Tract first ed. 2002 Churchill Livingstone London
15. M. Sawada H. Tsuda M. Kimura S. Okamoto T. Kita T. Kasamatsu T. Yamada Y. Kikuchi H. Honjo O. Matsubara Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoprotein between epithelial and mesenchymal components in uterine carcinosarcoma Cancer Sci. 94 2003 986-991
16. R. Seshadri F.A. Firgaira D.J. Horsfall K. McCaul V. Setlur P. Kitchen Clinical significance of HER-2/neu oncogene amplification in primary breast cancer J. Clin. Oncol. 11 1993 1936-1942
17. D.J. Slamon G.M. Clark S.G. Wong W.J. Levin A. Ullrich W.L. McGuire Human breast cancer: Correlation of relapse and survival with amplification of the HER2-2/neu oncogene Science 235 1987 177-182
18. D.J. Slamon B. Leyland-Jones S. Shak H. Fuchs V. Paton A. Bajamonde T. Fleming W. Eiermann J. Wolter M. Pegram J. Baselga L. Norton Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783-792
19. G. Smith J.C. Henderson New treatments for breast cancer Semin. Oncol. 23 1996 506-528
20. I. Treeilleux H. Mignatte C. Clement-chassagne P. Guastalla C. Bailly Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium: Report of six cases and review of the literature Eur. J. Surg. Oncol. 25 1999 477-482
21. M. Ursic Vrscaj S. Bebar A. Djurisic P.A. Fras Endometrial cancer after tamoxifen treatment of breast cancer: Result of a retrospective cohort study Eur. J. Gynecol. Oncol. 20 1999 10-25